Pediatric psoriasis: ustekinumab tops other biologics for drug survival

  • Phan C & al.
  • J Eur Acad Dermatol Venereol
  • 18 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results from an observational, retrospective study suggest that ustekinumab is associated with superior drug survival rates compared with adalimumab and etanercept in children with psoriasis.

Why this matters

  • Drug survival is an important factor affecting long-term performance in real-world settings.

Key results

  • Age at initiation (P<.001 age at onset of psoriasis and baseline severity were associated with choice first-line agent.>
  • Ustekinumab was associated with a higher drug survival rate compared with adalimumab and etanercept in the total cohort (P<.0001 style="list-style-type:circle;">
  • P=.0003 for patients with plaque-type psoriasis
  • P=.0007 for patients naive to biological agents
  • Discontinuation because of loss of efficacy was more frequent with etanercept (34.9%) compared with adalimumab (9.1%) and ustekinumab (0%).
  • Primary inefficacy was more common with etanercept (15.9%) compared with adalimumab (3.7%) and ustekinumab (2.9%).
  • Of 6 serious adverse events, 5 occurred in patients receiving adalimumab and 1 occurred in a patient receiving etanercept.
  • Study design

    • 134 children with psoriasis who underwent 184 treatment courses (70 etanercept, 68 adalimumab, 46 ustekinumab) were included.
    • Funding: None disclosed.

    Limitations

    • Potential reporting bias.
    • Retrospective study design.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit